中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

5987 records (took 0.061 seconds)

    Development of dengue virus vaccine components
    52.
    发明专利
    Development of dengue virus vaccine components 未知

    公开(公告)号：AU2021202950A1

    公开(公告)日：2021-06-03

    申请号：AU2021202950

    申请日：2021-05-10

    Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY

    Inventor： WHITEHEAD STEPHEN S ,  BLANEY JOSEPH E ,  MURPHY BRIAN R

    IPC: C12N7/00

    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3' untranslated region (3'-UTR) comprising a A30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the A30 mutation deleted from the 3'-UTR that removes sequence in the 5' direction as far as the 5'boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3'-UTR of a dengue virus of a first serotype with the 3'-UTR of a dengue virus of a second serotype, optionally containing the A30 mutation and nucleotides additional to the A30 mutation deleted from the 3'-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

    Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
    59.
    发明专利
    Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use 未知

    公开(公告)号：AU2012242784B2

    公开(公告)日：2017-04-13

    申请号：AU2012242784

    申请日：2012-04-12

    Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY

    Inventor： BURKE TERRENCE R ,  QIAN WENJIAN ,  LIU FA ,  LEE KYUNG S ,  PARK JUNG-EUN

    IPC: C07K14/435 ,  A61P35/00 ,  C12N9/12

    Abstract: Novel compounds are provided that bind to polo-like kinases through the polo -box domain. In certain embodiments, the novel compounds are PEGylated peptides. The PEGylated peptides in accordance with the invention demonstrate high PBD-binding affinity. In certain embodiments, the PEGylated peptides have also achieved activities in whole cell systems. The invention also provides compounds that bind polo- like kinases through the polo -box domain and possess reduced anionic charge. Further provided are methods of design and/or synthesis of the PEGylated peptides and methods of use thereof. The invention provides methods of use of the compounds and methods of synthesis of the compounds. The compounds of the invention have potential therapeutic activity in view of their binding and inhibitory activities towards Plkl. They are based on the amino acid sequence PLHSpT (phosphorylated Thr). The PEG moiety, when present, is covalently attached at the N- terminus. The invention also encompasses derivatives having substituents on the Pro and/or the His side chains, substituents on the phosphate group, the replacement of His with Gln, the replacement of Pro with a N-substituted Gly, the replacement of Ser with Ala, as well as HS-pT fragments with N-terminal alkoxycarbonyl group and PLHS fragments with a C-terminal glyco-imino-alkylxyalkylamide group.

    PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI
    60.
    发明专利
    PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI 未知

    公开(公告)号：AU2013205091B2

    公开(公告)日：2016-02-25

    申请号：AU2013205091

    申请日：2013-04-13

    Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY

    Inventor： BEALL BERNARD W ,  CARLONE GEORGE M ,  SAMPSON JACQUELYN S ,  ADES EDWIN W

    IPC: C07K14/315 ,  A61K39/00 ,  A61K39/02 ,  A61K39/09 ,  C12N1/21

    Abstract: This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross- reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines. WO 02/094851 PCT/US02/15909 Number of Isolate 20.7%%m1mu 8.3% emm2 uD 4.1% emm4 o O 3.7% emm8 () r-r 2.8% emm77/27 (D Cl. 2.5% emmx2 2.2% emm4 (D 1.8% emm3 1.7% emm5 1.6% emm2 0 1.5% emml 1.2% emm5

Patent Agency Ranking